ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Premium Icon프리미엄 Help Menu
S&P 500
5,976.97
-1.13%
US Tech 100
21,079.20
-1.25%
다우존스 지수
42,197.79
-1.79%
Bitcoin
104,965.51
-0.47%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE

  6. Merck and Co Inc (MRK) 시세

Merck and Co Inc

Merck and Co Inc (MRK)

Marks Electrical Group Plc
Merck KGAA
81.71
-0.11
(-0.13%)
마감 15 6월 5:00AM
15분 지연 - 실시간으로 업그레이드
82.14
0.43
(0.53%)
시간외 거래: 8:55AM
15분 지연 - 실시간으로 업그레이드

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
82.14
매수가
-
매도가
-
거래량
14,550,532
81.45 일간 변동폭 82.44
73.31 52주 범위 134.63
market_cap
206.256B
전일 종가
81.82
개장가
81.65
최근 거래 시간
1
@
81.9
마지막 거래 시간
재정 규모
US$ 1,192,299,606
VWAP
81.942
평균 볼륨(3m)
15,598,816
발행 주식
2,511,031,253
배당수익률
3.94%
주가수익률
11.99
주당순이익(EPS)
6.82
매출
64.17B
순이익
17.12B

Merck and Co Inc 정보

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.merck.com
본부
West Trenton, New Jersey, USA
설립됨
-
Merck and Co Inc is listed in the Pharmaceutical Preparations sector of the 뉴욕 증권거래소 with ticker MRK. The last closing price for Merck was US$81.82. Over the last year, Merck shares have traded in a share price range of US$ 73.31 to US$ 134.63.

Merck currently has 2,511,031,253 shares in issue. The market capitalisation of Merck is US$205.45 billion. Merck has a price to earnings ratio (PE ratio) of 11.99.

Merck (MRK) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

강세

순 프리미엄

33M

Calls / Puts

486.67%

매수 / 매도

108.86%

OTM / ITM

39.68%

Sweeps 비율

0.00%

MRK 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 6월 2025
MRK (-0.13%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 6월 2025
MRK (-0.13%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 6월 2025
MRK (-0.13%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 6월 2025
MRK (-0.13%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
13.834.8908185416978.3182.1478.211326462780.34933507CS
46.989.2868547099575.1682.1474.36751330638977.9726535CS
12-12.44-13.152886445394.5894.7473.311559881680.5299251CS
26-18.99-18.7778107387101.13102.9773.311494062086.98519597CS
52-47.97-36.8688033203130.11134.6373.311243584997.16291813CS
156-3.37-3.941059525285.51134.6373.319634142103.17486195CS
2607.189.5784418356574.96134.6370.891032479692.69320341CS

MRK - Frequently Asked Questions (FAQ)

What is the current Merck share price?
The current share price of Merck is US$ 82.14
How many Merck shares are in issue?
Merck has 2,511,031,253 shares in issue
What is the market cap of Merck?
The market capitalisation of Merck is USD 205.45B
What is the 1 year trading range for Merck share price?
Merck has traded in the range of US$ 73.31 to US$ 134.63 during the past year
What is the PE ratio of Merck?
The price to earnings ratio of Merck is 11.99
What is the cash to sales ratio of Merck?
The cash to sales ratio of Merck is 3.2
What is the reporting currency for Merck?
Merck reports financial results in USD
What is the latest annual turnover for Merck?
The latest annual turnover of Merck is USD 64.17B
What is the latest annual profit for Merck?
The latest annual profit of Merck is USD 17.12B
What is the registered address of Merck?
The registered address for Merck is 820 BEAR TAVERN ROAD, WEST TRENTON, NEW JERSEY, 08628 1021
What is the Merck website address?
The website address for Merck is www.merck.com
Which industry sector does Merck operate in?
Merck operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CRCLCircle Internet Group Inc
US$ 133.80
(25.59%)
34.01M
NINENine Energy Service Inc
US$ 0.7366
(25.02%)
56.22M
NYCAmerican Strategic Investment Co
US$ 10.50
(12.99%)
1.61k
CNFCNFinance Holdings Limited
US$ 0.4919
(12.28%)
57.31k
SSLSasol Ltd
US$ 5.44
(12.16%)
3.38M
TGEGeneration Essentials Group
US$ 7.3614
(-22.18%)
356.46k
SUPSuperior Industries International
US$ 0.33
(-21.93%)
1.79M
XINXinyuan Real Estate Co Ltd
US$ 2.02
(-18.88%)
15.77k
ACHRArcher Aviation Inc
US$ 9.9899
(-14.83%)
111.01M
PROPros Holding Inc
US$ 15.74
(-13.04%)
2.17M
ACHRArcher Aviation Inc
US$ 9.9899
(-14.83%)
111.01M
BBAIBigBear ai Holdings Inc
US$ 3.715
(-3.00%)
95.9M
FFord Motor Company
US$ 10.44
(-0.85%)
90.11M
BTEBaytex Energy Corporation
US$ 2.09
(3.98%)
73.32M
RIGTransocean Ltd
US$ 3.315
(3.27%)
66.55M

MRK Discussion

게시물 보기
BottomBounce BottomBounce 1 월 전
Veterinarians across the country are currently injecting experimental self-amplifying RNA shots into our dogs and cats: Nobivac NXT by Merck

These injections are currently widely available for online purchase.

The so-called “safety” data for these injections is as follows:… https://t.co/RHYlOkRYyx pic.twitter.com/Hdd87jCShf— Nicolas Hulscher, MPH (@NicHulscher) April 25, 2025 $MRK
👍️0
wagner wagner 1 월 전
Interesting bottom coming in..... 🤔🤫🤔
👍️0
BottomBounce BottomBounce 1 월 전
WOW: RFK Jr: “The MMR vaccine that we currently use has millions of particles that were created from aborted fetal tissue, millions of DNA fragments.” pic.twitter.com/Y0qrVPnbHD— Died Suddenly (@DiedSuddenly_) May 10, 2025 $MRK
👍️0
axelvento axelvento 2 월 전
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

bottom

https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/
👍 1
axelvento axelvento 2 월 전
botton play
👍️0
Monksdream Monksdream 2 월 전
MRK, new 52 week low this week
👍️0
axelvento axelvento 3 월 전
Merck wins Gardasil litigation over cancer vaccine risks

On Tuesday, Merck & Co (NYSE:MRK) Inc. emerged victorious in a significant legal dispute concerning its Gardasil vaccine, which is designed to prevent cervical and other serious cancers. U.S. District Judge Kenneth Bell, presiding in Charlotte, North Carolina, dismissed more than 200 cases that were part of a consolidated multidistrict litigation.

The plaintiffs in the litigation had accused Merck (NSE:PROR) of failing to warn about potential side effects of Gardasil, specifically an increase in heart rate and ovarian issues. They contended that these warnings should have been included on the vaccine’s labels. However, Judge Bell determined that under federal law, Merck did not have the power to independently add warnings about such risks without more substantial evidence.

In his decision, Bell emphasized the importance of not deterring the use of vaccines that save lives with warnings that are not well-supported by evidence. He stated that federal law demands more than "speculative inferences" before imposing severe warnings on vaccines, which could potentially dissuade people from using them.

Merck responded to the ruling with approval, stating that they were "extremely pleased" with the outcome. The decision effectively resolves a large group of claims that had been brought against the pharmaceutical company regarding its Gardasil vaccine.

This ruling supports the position that vaccine manufacturers are not responsible for independently updating warnings on their products without the explicit direction of the Food and Drug Administration or a solid foundation of scientific proof. The dismissal of the cases underscores the legal protections in place for vaccine makers, especially when the allegations are not substantiated by robust scientific data.
👍️ 1
BLACKBIRDSR-71 BLACKBIRDSR-71 10 월 전
SPECULATION OF ALL CANCER NATIONS BREAKTHROUGH DECLARED
👍️0
BLACKBIRDSR-71 BLACKBIRDSR-71 10 월 전
Cancer breakthrough in the clinic broski Rnaz https://www.eurekalert.org/news-releases/1055915
👍️0
ZLAZARUS ZLAZARUS 10 월 전
Picked up a few hundred shares today
👍️0
DewDiligence DewDiligence 11 월 전
MRK 2Q24 results:

https://www.businesswire.com/news/home/20240730509685/en
👍️0
DewDiligence DewDiligence 11 월 전
MRK’s RSV prophylactic, Clesrovimab meets_all_endpoints_in_phase-2/3_trial:

https://www.businesswire.com/news/home/20240723229019/en

If approved, Clesrovimab will compete against GSK’s Beyfortus.

Beyfortus and Clesrovimab are effective at preventing RSV for one season, but they do not confer lasting immunity. Patients taking these drugs are likely to contract RSV infection in a subsequent season, and hence the need for RSV treatments, such as those being developed by ENTA, is not diminished.
👍️0
ShadowVolcano37 ShadowVolcano37 11 월 전
MRK is doing really well. Wish I invested two years ago. Personalized Immunotherapy is going to be a huge thing very soon. So maybe it's not too late.
👍️0
DewDiligence DewDiligence 12 월 전
ACIP endorses MRK’s Capvaxive pneumococcal vaccine for certain groups—creating parity with PFE’s Prevnar-13 for adult market:

https://www.businesswire.com/news/home/20240627540619/en
• Adults 65 years of age and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19 years of age and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) [PFE’s Prevnar-13] but have not received all recommended PPSV23 [MRK’s Pneumovax]…;

• Additionally, shared clinical decision-making is recommended regarding use of a supplemental dose of CAPVAXIVE for adults 65 years of age and older who have completed their vaccine series with both PCV13 [Prevnar-13] and PPSV23 [Pneumovax]. These ACIP recommendations are essentially the same as the CDC’s existing recommendations for PFE’s Prevnar-20, and hence they should allow MRK’s Capvaxive to gain a meaningful share in the adult portion of the pneumococcal vaccine market. PFE has had an overwhelming (>90%) share of this market in the US because MRK’s other conjugated pneumococcal vaccine, Vaxneuvance, received a less favorable recommendation from the CDC than PFE’s Prevnar-13.

Please see #msg-166441188 and #msg-172452293 for related info.
👍️0
DewDiligence DewDiligence 12 월 전
FDA approves MRK’s Capvaxive—(f/k/a V116)—pneumococcal vaccine for adults:

https://www.businesswire.com/news/home/20240614126575/en

With this approval, MRK should finally get a decent share of the market for adult pneumococcal vaccines, where PFE’s Prevnar franchise has long been dominant.

Please see #msg-173458310 and #msg-172452293 for related info.
👍️0
avxl_going_long avxl_going_long 1 년 전
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
axelvento axelvento 1 년 전
https://www.onclive.com/view/pembrolizumab-plus-concurrent-crt-meets-os-end-point-in-high-risk-locally-advanced-cervical-cancer
👍️0
axelvento axelvento 1 년 전
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients

KEYNOTE-A18, also known as ENGOT-cx11/GOG-3047, is a randomized, double-blind Phase 3 trial

https://www.biospace.com/article/releases/merck-s-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-significantly-improved-overall-survival-os-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/?keywords=pancreatic+cancer+phase+3
👍️0
Monksdream Monksdream 1 년 전
MRK new 52 week high
👍️0
fly123 fly123 1 년 전
Bought 11% of EVAX
👍️0
snoopycomic snoopycomic 2 년 전
Why Red fonts?
👍️0
DewDiligence DewDiligence 2 년 전
MRK reports 2Q23 results…

PR:
https://www.businesswire.com/news/home/20230801830764/en

Reuters:
https://finance.yahoo.com/news/1-merck-beats-quarterly-sales-104937970.html Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil, sailed past Wall Street estimates.

Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.

…Sales of Gardasil…surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. MRK sharply lowered 2023 non-GAAP EPS guidance due to a $10.2B charge ($4.02/sh) relating to in-process R&D from the acquisition of RXDX (#msg-171696785). The new guidance range is $2.95-3.05.
👍️0
DewDiligence DewDiligence 2 년 전
MRK’s V116 shows non-inferiority to Prevnar-20 in two phase-3 trials (one for pneumococcal-vaccine naïve patients and one for patients who received a prior pneumococcal vaccine):

https://www.businesswire.com/news/home/20230727120762/en

V116 is a 21-valent pneumococcal vaccine intended for the adult market only. PFE’s Prevnar-20 currently owns virtually the entire adult market for pneumococcal vaccines because CDC/ACIP’s recommendations give preferential treatment to Prevnar-20 vs MRK’s 15-valent V114 (a/k/a Vaxneuvance) (#msg-166441188).

The V116 results announced today put MRK back in the ballgame for the adult segment of the market.

See #msg-168548763 for related info.
👍️0
DewDiligence DewDiligence 2 년 전
MRK sues US over IRA drug-price “negotiation”:

https://www.wsj.com/articles/merck-challenges-u-s-governments-new-powers-to-negotiate-drug-prices-127d4b0c Drugmaker Merck & Co. filed a lawsuit on Tuesday challenging the U.S. government’s plan to negotiate drug prices, saying it is unconstitutional.

Drugmakers were expected to file lawsuits challenging the program, especially as Medicare neared the date later this year when it began naming some drugs it would target for price negotiations.

Among the drugs that analysts expected to face price negotiations are Merck’s top-selling product, the cancer immunotherapy Keytruda.

Merck’s complaint takes issue with the negotiation program’s enforcement rules, which include the power to levy an excise tax of up to 95% of a drug’s U.S. sales if a pharmaceutical company refuses to sell the drug to Medicare patients. Merck said the tax would be coercive and violate the constitution’s Fifth Amendment ban on private property being taken for public use without just compensation. [The so-called “takings” clause.]

Merck also said the law would force companies to agree that the government-mandated prices are “fair,” violating its free speech rights under the First Amendment. For biotech investors, there’s a lot riding on the outcome of this lawsuit and related cases.

Want more details? See https://www.cms.gov/files/document/medicare-drug-price-negotiation-program-initial-guidance.pdf (91 pages).
👍️0
DewDiligence DewDiligence 2 년 전
MRK’s ASCO lineup:

https://finance.yahoo.com/news/merck-present-extensive-research-demonstrating-104500565.html
👍️0
DewDiligence DewDiligence 2 년 전
MRK reports 1Q23 results—raises non-GAAP EPS guidance:

https://finance.yahoo.com/news/merck-announces-first-quarter-2023-103000788.html

https://finance.yahoo.com/news/merck-earnings-better-expected-keytruda-103855413.html

2023 non-GAAP EPS guidance was raised to $6.88-7.00 (from $6.80-6.95).
👍️0
DewDiligence DewDiligence 2 년 전
MRK acquires RXDX for $10.8B…

PR:
https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/

CC slides:
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Acquisition-of-Prometheus-Biosciences-Investor-Event-Slides-FINAL.pdf
👍️0
DewDiligence DewDiligence 2 년 전
A Delaware judge ruled today that MRK remains liable for talc lawsuits relating to Dr. Scholl’s foot powder, even though MRK sold its OTC- healthcare business to Bayer in 2014:

https://finance.yahoo.com/news/bayer-defeats-merck-lawsuit-over-215120183.html

MRK inherited Dr. Scholl’s in the 2009 takeover of Schering-Plough.
👍️0
DewDiligence DewDiligence 2 년 전
Keytruda shows statsig-superior PFS as addend to chemo in Stage-III/IV (or recurrent) endometrial cancer:

https://www.businesswire.com/news/home/20230327005147/en

The HR for PFS was 0.54 in the pMMR subgroup and 0.30(!) in the dMMR subgroup.

The OS results are not disclosed in the PR, so they are presumably not mature. (OS was a secondary endpoint.)
👍️0
DewDiligence DewDiligence 2 년 전
EMA rejects MRK’s MAA for Molnipiravir:

https://www.businesswire.com/news/home/20230223006077/en Merck and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for LAGEVRIO (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union (EU). Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion. The appeal would seem to be fruitless. Molnupiravir is simply a bad drug that doesn’t deserve (non-emergency) marketing authorization.
👍️0
DewDiligence DewDiligence 2 년 전
MRK 4Q22 results—2023 guidance:

https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Merck-News-Release-02-02-23-Merck-Announces-4Q-and-FY-2022-Financial-Results.pdf

2023 guidance for non-GAAP EPS is $6.80-6.95; at the midpoint, this is an 8% decline from 2022’s $7.48.

CC slides:
https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Q4-2022-Merck-Earnings-Deck-(Final).pdf

Prepared remarks:
https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Q4-2022-Merck-Earnings-Prepared-Remarks-(Final).pdf
👍️0
DewDiligence DewDiligence 2 년 전
FDA approves Keytruda for adjuvant NSCLC following adjuvant treatment with platinum chemo:

https://www.businesswire.com/news/home/20230127005078/en

Keytruda’s HR for DFS (compared to placebo) was 0.73 [95% CI: 0.60-0.89]. This is slightly better than the HR=0.76 that MRK reported when the KEYNOTE-091 trial reported in Mar 2022 (#msg-168241140); I do not know the reason for the discrepancy.

Curiously, in an exploratory analysis of patients (n=167) who did not receive adjuvant chemo, Keytruda’s HR for DFS (relative to placebo) was 1.25 (i.e. the Keytruda arm did worse than placebo), but the 95% confidence interval was wide [0.76-2.05].
👍️0
extrooper extrooper 2 년 전
That would be the best , most productive purchase they could ever make , but Merck mgt is too stupid. They try to build equivalent to DCVax with every asinine purchase they make. Maybe a new mgt team at Merck with common sense, would get DCVax , the most incredible advancement in GBM and immunology in history.
👍️0
DewDiligence DewDiligence 2 년 전
Keytruda fails again in prostate cancer—one of the few cancer indications where it has not seen a positive outcome:

https://www.businesswire.com/news/home/20230124006084/en/Merck-Announces-KEYNOTE-991-Trial-Evaluating-KEYTRUDA%C2%AE-pembrolizumab-Plus-Enzalutamide-and-Androgen-Deprivation-Therapy-in-Patients-With-Metastatic-Hormone-Sensitive-Prostate-Cancer-to-Stop-for-Futility Merck…today announced that it will stop the Phase 3 KEYNOTE-991 trial investigating KEYTRUDA…in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

…At the interim analysis, KEYTRUDA in combination with enzalutamide [Xtandi] and ADT did not demonstrate an improvement in overall survival (OS) or radiographic progression-free survival (rPFS), the trial’s dual primary endpoints, compared to placebo plus enzalutamide and ADT. This is Keytruda’s third recent phase-3 in prostate cancer. In the KEYNOTE-921 trial, which reported results in Aug 2021, Keytruda failed to show a statsig benefit when added to chemo in CRPC (#msg-169574792). In the KEYLINK-010 study, which reported results in Mar 2022, the combination of Keytruda and Lynparza (a PARP inhibitor) failed to show a statisig benefit compared to Xtandi or Zytiga in mCPRC refractory to chemo and either of Xtandi or Zytiga (https://www.clinicaltrials.gov/ct2/show/NCT03834519 ).

Keytruda is a great drug, but it’s not invincible.
👍️0
Pattyloco Pattyloco 2 년 전
Why
👍️0
DewDiligence DewDiligence 2 년 전
The MRK-SGEN deal reputed to be nearly done last summer (#msg-169332904) can probably be dismissed after MRK’s ADC collaboration with China’s Kelun-Biotech today:

https://finance.yahoo.com/news/merck-kelun-biotech-announce-exclusive-114500834.html
👍️0
DewDiligence DewDiligence 3 년 전
MRK/MRNA cancer vaccine shines in adjuvant melanoma (RFS HR=0.56):

https://www.accesswire.com/731571/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial …the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA…demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.

Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone. Note: If this had been a phase-3 trial, it would’ve been considered a failure since the standard cutoff for a one-sided p-value is 0.025. For a phase-2b, however, these results are just fine.
👍️0
DewDiligence DewDiligence 3 년 전
MRK acquires IMGO for $36.00/sh cash—a 107% premium to Friday’s close:

https://finance.yahoo.com/news/merck-acquire-imago-biosciences-inc-114500059.html

The nominal deal value is $1.35B. The buyout price is a 125% premium to IMGO’s IPO price 16 months ago (#msg-164945919).
👍️0
DewDiligence DewDiligence 3 년 전
I would take the other side of that bet!
👍️0
Pattyloco Pattyloco 3 년 전
Ehhhhh seems a lot more likely today
👍️0
DewDiligence DewDiligence 3 년 전
Unlikely, haha.
👍️0
Pattyloco Pattyloco 3 년 전
NWBO next purchase of Merck?
👍️0
DewDiligence DewDiligence 3 년 전
MRK 3Q22 CC slides:

https://s21.q4cdn.com/488056881/files/doc_financials/2022/q3/Q3-2022-Merck-Earnings-Deck-(Final).pdf
👍️0
DewDiligence DewDiligence 3 년 전
MRK 3Q22 results:

https://finance.yahoo.com/news/merck-announces-third-quarter-2022-103000305.html
👍️0
DewDiligence DewDiligence 3 년 전
MRK exercises option_to_commercialize MRNA cancer vaccine:

https://www.accesswire.com/720004/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine

https://finance.yahoo.com/news/1-merck-opts-jointly-develop-113551661.html

MRNA receives $250M in immediate cash from MRK’s opt-in.
👍️0
DewDiligence DewDiligence 3 년 전
Sotatercept phase-3 in PAH hits primary endpoint:

https://finance.yahoo.com/news/merck-announces-positive-top-line-104500840.html

Sotatercept is the drug MRK picked up in the $11.5B XLRN acquisitions last year (#msg-166156870).
👍️0
DewDiligence DewDiligence 3 년 전
Lagevrio misses_primary_endpoint_in_large_Oxford_U_trial:

https://ca.finance.yahoo.com/news/merck-ridgeback-biotherapeutics-clinical-non-235000071.html The PANORAMIC study, a UK-based clinical trial sponsored by the University of Oxford, included 25,783 participants who were randomized to open label treatment with LAGEVRIO plus usual care (n=12,821) or usual care alone (n=12,962); mean age of participants was 56.6 years. Primary outcome data were available in 25,000 (97%) participants. Nearly all (>98%) participants were vaccinated, with approximately 95% receiving three or more doses of a SARS-CoV-2 vaccine.

In the preliminary analysis, the primary endpoint of reduction of hospitalizations and deaths within 28 days of randomization, compared to usual care, was not met; 0.8% of patients in both the LAGEVRIO group (n=103/12,516) and the usual care group (n=96/12,484) were hospitalized or died in the first 28 days. Separately, in a retrospective study based on electronic medical records of high-risk patients in Israel, Lagevrio showed a benefit in reducing hospitalizations and death in the patients age 65+ but not in patients age 40-64.

Bottom line: Legevrio (molnupiravir) remains a poor choice for treating COVID. It is being prescribed only when Paxlovid is either unavailable or contra-indicated due to drug-drug interactions (from ritonavir).
👍️0
DewDiligence DewDiligence 3 년 전
FDA allows some Islatravir trials to_resume_at_a lower dose:

https://finance.yahoo.com/news/merck-initiate-phase-3-clinical-104500524.html
👍️0
DewDiligence DewDiligence 3 년 전
Keytruda narrowly_misses_statsig OS/PFS as_addend_to Lenvina in_ first-line HCC:

https://finance.yahoo.com/news/merck-eisai-present-results-phase-063000955.html

In the final analysis of the trial, there was a trend toward improvement for one of the study’s dual primary endpoints, overall survival (OS), for patients treated with KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, the results did not meet statistical significance per the pre-specified statistical plan (HR=0.84 [95% CI: 0.71-1.00]; p=0.0227). The median OS was 21.2 months (95% CI: 19.0-23.6) for KEYTRUDA plus LENVIMA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy.

Additionally, treatment with KEYTRUDA plus LENVIMA resulted in a trend toward improvement in the trial’s other dual primary endpoint of progression-free survival (PFS) versus LENVIMA monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance (HR=0.87 [95% CI: 0.73-1.02]; p=0.0466). These results were presented at ESMO.
👍️0
TechandBio TechandBio 3 년 전
Merck snatched up ROR1 veslobio for 2.75 Billion I think they may try and Buy ONCT better acting drug partnered with ABBV ibrutinib the combo works 50% better than the drug alone. Pcyc ibrutinib now ABBV is going to do 9.5-10 Billion in sales next year. I think Merck might buy ONCT more data further along in trials very robust pipeline. ROR1 expression on many tumor types
• Potential safety and efficacy advantages
• MK-2140 ADC data at ASH 2021: no apparent off-
tumor, on-target ROR1 toxicities.
ROR1 Expressed on Multiple
Solid and Liquid Tumor's
MCL 95%
CLL 95%
Uterus 96%
Lymphoma 90%
Prostate 90%
Skin 89%
Insiders have been buying it up just broke the 50 day moving average. I think Merck might come in to add to there Ror1 portfolio.
https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race

$MRK
👍️0

최근 히스토리

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN Ltd - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지